Company: BGLC
Filing Date: 2025-10-23
Form Type: 8-K
Source: 0001477932-25-007708
Chunk: 0

Company: BioNexus Gene Lab Corp
Filing Date: 2025-10-23
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01. Regulation FD Disclosure.

On October 20, 2025, BioNexus Gene Lab Corp (the “ Company” or “ BGLC”) issued a press release announcing that it had entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. (“ Birch”), a Canadian biotechnology company developing regenerative treatments for organ fibrosis, topical scarring, and autoimmune diseases.

The Term Sheet outlines the principal terms of a proposed collaboration under which BGLC would lead Birch’s current financing round through a strategic equity investment and joint commercialization of Birch’s FS2 (kynurenic acid) topical platform in Southeast Asia. The Term Sheet is non-binding and intended solely as a framework for continued discussions. There can be no assurance that a definitive agreement will be executed or that the proposed transactions will be completed on the terms contemplated or at all.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statement and Exhibits.